ADPA-2M4CD8 is a gene-modified cell therapy commercialized by Adaptimmune Therapeutics, with a leading Phase II program in Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ADPA-2M4CD8’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ADPA-2M4CD8 is expected to reach an annual total of $31 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ADP-A2M4CD8 is under development for the treatment of solid tumors including platinum-resistant ovarian cancer, urothelial carcinoma, endometrial cancer, esophageal cancer, melanoma, esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), peritoneal cancer, fallopian tube cancer and head and neck cancer. The therapeutic candidate comprises of CD8 alpha co-receptor alongside the autologous genetically modified engineered TCR that targets MAGE-A4. It is a next-generation of ADP-A2M4 which is administered by parenteral and intravenous route. It is developed based on SPEAR T-cell platform.
It was under development for synovial sarcoma, myxoid, round cell liposarcoma and bladder cancer.
Adaptimmune Therapeutics Overview
Adaptimmune Therapeutics (Adaptimmune) is a clinical-stage biopharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. The company product pipeline includes afami cel, ADP-A2M4CD8 and ADP-A2AFP. It treats synovial sarcoma, head and neck, urothelial, esophageal, EGJ cancer and hepatocellular carcinoma. Adaptimmune has collaborated with Alpine Immune Sciences, Cell and Gene Therapy Catapult, Center for Cancer ImmunTherapy, Genentech and MD Anderson Cancer Center, among others. The company has operations across the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.
The company reported revenues of (US Dollars) US$27.2 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$6.2 million in FY2021. The operating loss of the company was US$164 million in FY2022, compared to an operating loss of US$162.3 million in FY2021. The net loss of the company was US$165.5 million in FY2022, compared to a net loss of US$158.1 million in FY2021. The company reported revenues of US$7.3 million for the third quarter ended September 2023, an increase of 42.7% over the previous quarter.
For a complete picture of ADPA-2M4CD8’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.